Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 7/20 | 0.63 |
| ▸ | GSK3B | P49841 | 7/20 | 0.63 |
| ▸ | FADS1 | O60427 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801696 | 0.89 | GSK3A (0.58) | GSK3AGSK3BFADS1RIPK2EGFR | |
| SCHEMBL802691 | 0.89 | GSK3A (0.46) | GSK3AGSK3BFADS1S1PR1S1PR5 | |
| SCHEMBL805596 | 0.88 | GSK3A (0.56) | GSK3AGSK3BFADS1RIPK2MAPT | |
| SCHEMBL802321 | 0.84 | GSK3A (0.56) | GSK3AGSK3BFADS1RIPK2EGFR | |
| SCHEMBL801730 | 0.79 | FADS1 (0.45) | GSK3AGSK3BFADS1RIPK2EGFR | |
| SCHEMBL12303117 | 0.78 | GSK3A (1.00) | GSK3AGSK3BFADS1RIPK2EGFR | |
| SCHEMBL802704 | 0.77 | GSK3A (0.42) | GSK3AGSK3BFADS1PDE5AALDH1A1 | |
| SCHEMBL805543 | 0.77 | USP1 (0.49) | GSK3AGSK3BPDE5AMAPTALDH1A1 | |
| SCHEMBL12303092 | 0.76 | GSK3A (0.98) | GSK3AGSK3BFADS1RIPK2EGFR | |
| SCHEMBL13938155 | 0.76 | CYP1A2 (0.54) | GSK3AGSK3BFADS1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | GSK3A 2/4885GSK3B 1/4885FADS1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.